We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+2.78%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.04B
AUM Growth
-$13.5M
Cap. Flow
+$810K
Cap. Flow %
0.08%
Top 10 Hldgs %
35.44%
Holding
98
New
14
Increased
36
Reduced
31
Closed
5

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$31.8M
2
DHR icon
Danaher
DHR
+$9.47M
3
EW icon
Edwards Lifesciences
EW
+$8.63M
4
ELV icon
Elevance Health
ELV
+$8.62M
5
GILD icon
Gilead Sciences
GILD
+$7.44M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$21.7M
2
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$20.8M
3
THC icon
Tenet Healthcare
THC
+$18.2M
4
MDT icon
Medtronic
MDT
+$9.59M
5
ZBH icon
Zimmer Biomet
ZBH
+$8.91M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
1
UnitedHealth
UNH
$376B
$53.6M 5.15%
105,300
+64,800
+160% +$31.8M
ELV icon
2
Elevance Health
ELV
$81.5B
$46.5M 4.46%
85,800
+16,300
+23% +$8.62M
BSX icon
3
Boston Scientific
BSX
$69.5B
$45.8M 4.4%
595,000
+13,000
+2% +$952K
LLY icon
4
Eli Lilly
LLY
$1.02T
$42.6M 4.09%
47,000
-7,175
-13% -$5.74M
REGN icon
5
Regeneron Pharmaceuticals
REGN
$78.5B
$33.6M 3.23%
32,000
-2,300
-7% -$2.23M
ABBV icon
6
AbbVie
ABBV
$443B
$32.4M 3.11%
189,000
-500
-0.3% -$82.8K
THC icon
7
Tenet Healthcare
THC
$20.5B
$30.5M 2.92%
229,000
-151,000
-40% -$18.2M
OSCR icon
8
Oscar Health
OSCR
$9.41B
$30.2M 2.9%
1,906,611
+215,089
+13% +$3.95M
COO icon
9
Cooper Companies
COO
$14.1B
$27.1M 2.6%
310,000
+9,000
+3% +$840K
ISRG icon
10
Intuitive Surgical
ISRG
$127B
$26.9M 2.58%
60,500
+10,000
+20% +$3.98M
PRCT icon
11
Procept Biorobotics
PRCT
$1.06B
$26.9M 2.58%
440,000
-47,063
-10% -$2.8M
BDX icon
12
Becton Dickinson
BDX
$45.6B
$26.4M 2.54%
113,000
-3,000
-3% -$707K
HCA icon
13
HCA Healthcare
HCA
$87.2B
$26.3M 2.53%
82,000
-18,000
-18% -$5.85M
VRTX icon
14
Vertex Pharmaceuticals
VRTX
$121B
$25.3M 2.43%
54,000
-2,500
-4% -$1.09M
CI icon
15
Cigna
CI
$73.7B
$24.5M 2.35%
74,171
-63,000
-46% -$21.7M
MRK icon
16
Merck
MRK
$322B
$21.7M 2.08%
175,000
-43,500
-20% -$5.6M
ALNY icon
17
Alnylam Pharmaceuticals
ALNY
$27.5B
$20.8M 1.99%
85,500
+43,200
+102% +$6.82M
BMRN icon
18
BioMarin Pharmaceuticals
BMRN
$11.6B
$20.7M 1.99%
251,500
+14,000
+6% +$1.17M
BIIB icon
19
Biogen
BIIB
$30B
$19.7M 1.89%
84,800
+28,000
+49% +$6.09M
MCK icon
20
McKesson
MCK
$100B
$17.5M 1.68%
30,000
-14,000
-32% -$7.79M
NTRA icon
21
Natera
NTRA
$38.3B
$17M 1.63%
157,000
-83,000
-35% -$8.43M
MDT icon
22
Medtronic
MDT
$109B
$16.4M 1.57%
208,000
-117,000
-36% -$9.59M
GILD icon
23
Gilead Sciences
GILD
$162B
$16.4M 1.57%
238,500
+111,500
+88% +$7.44M
ABT icon
24
Abbott
ABT
$183B
$15.1M 1.45%
145,000
-40,000
-22% -$4.24M
RPRX icon
25
Royalty Pharma
RPRX
$25.9B
$14.4M 1.38%
544,697
– –
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2024 Portfolio in Review

As of Q2 2024, Rhenman & Partners Asset Management held 98 positions worth $1.04B, down 1.3% from $1.06B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rhenman & Partners Asset Management's Q2 2024 filing shows 14 new, 36 increased, 31 reduced and 5 closed positions. Its largest new stake was Edwards Lifesciences: 97,500 shares worth $9.01M. The largest sale was Cigna, an estimated $21.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials.

  • Rhenman & Partners Asset Management's largest Q2 2024 buy was Edwards Lifesciences: 97,500 shares worth $9.01M.
  • Rhenman & Partners Asset Management added most to UnitedHealth in Q2 2024, an estimated $31.8M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2024 reduction was Cigna, cutting an estimated $21.7M.
  • Rhenman & Partners Asset Management fully exited Shockwave Medical, Inc. Common Stock in Q2 2024, selling an estimated $20.8M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 35% of its $1.04B portfolio in Q2 2024.
  • Rhenman & Partners Asset Management opened 14 new positions and closed 5 in Q2 2024.
  • Rhenman & Partners Asset Management's portfolio value fell 1.3% quarter-over-quarter to $1.04B.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.